{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T01:57:48Z","timestamp":1783648668740,"version":"3.55.0"},"reference-count":23,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinical-genitourinary-cancer.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Genitourinary Cancer"],"published-print":{"date-parts":[[2023,8]]},"DOI":"10.1016\/j.clgc.2023.04.008","type":"journal-article","created":{"date-parts":[[2023,4,24]],"date-time":"2023-04-24T21:15:10Z","timestamp":1682370910000},"page":"483-490","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":21,"title":["Outcomes of Second-Line Therapies in Patients With Metastatic de Novo and Treatment-Emergent Neuroendocrine Prostate Cancer: A Multi-Institutional Study"],"prefix":"10.1016","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8430-1040","authenticated-orcid":false,"given":"Corbin J.","family":"Eule","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junxiao","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sulaiman","family":"Al-Saad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0485-8031","authenticated-orcid":false,"given":"Katharine","family":"Collier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6629-9568","authenticated-orcid":false,"given":"Patrick","family":"Boland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7347-1861","authenticated-orcid":false,"given":"Akeem R.","family":"Lewis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rana R.","family":"McKay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8205-738X","authenticated-orcid":false,"given":"Vivek","family":"Narayan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominick","family":"Bosse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2122-6805","authenticated-orcid":false,"given":"Amir","family":"Mortazavi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1411-2487","authenticated-orcid":false,"given":"Tracy L.","family":"Rose","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1753-5928","authenticated-orcid":false,"given":"Brian A.","family":"Costello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0206-3895","authenticated-orcid":false,"given":"Alan H.","family":"Bryce","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5629-3402","authenticated-orcid":false,"given":"Elaine T.","family":"Lam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clgc.2023.04.008_bib0001","doi-asserted-by":"crossref","first-page":"3792","DOI":"10.3390\/cancers12123792","article-title":"Neuroendocrine and aggressive-variant prostate cancer","volume":"12","author":"Spetsieris","year":"2020","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.clgc.2023.04.008_bib0002","doi-asserted-by":"crossref","first-page":"719","DOI":"10.6004\/jnccn.2014.0073","article-title":"Neuroendocrine prostate cancer: subtypes, biology, and clinical outcomes","volume":"12","author":"Aggarwal","year":"2014","journal-title":"J Natl Compr Canc Netw"},{"key":"10.1016\/j.clgc.2023.04.008_bib0003","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.ejca.2019.08.011","article-title":"Clinical features of neuroendocrine prostate cancer","volume":"121","author":"Conteduca","year":"2019","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.clgc.2023.04.008_bib0004","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1097\/PAS.0000000000000208","article-title":"Proposed morphologic classification of prostate cancer with neuroendocrine differentiation","volume":"38","author":"Epstein","year":"2014","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.clgc.2023.04.008_bib0005","doi-asserted-by":"crossref","first-page":"2846","DOI":"10.1158\/1078-0432.CCR-13-3309","article-title":"Aggressive variants of castration-resistant prostate cancer","volume":"20","author":"Beltran","year":"2014","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clgc.2023.04.008_bib0006","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1016\/j.eururo.2021.12.039","article-title":"Pre-existing castration-resistant prostate cancer-like cells in primary prostate cancer promote resistance to hormonal therapy","volume":"81","author":"Cheng","year":"2022","journal-title":"Eur Urol"},{"key":"10.1016\/j.clgc.2023.04.008_bib0007","doi-asserted-by":"crossref","first-page":"3372","DOI":"10.1038\/s41467-021-23780-y","article-title":"Temporal evolution of cellular heterogeneity during the progression to advanced AR-negative prostate cancer","volume":"12","author":"Brady","year":"2021","journal-title":"Nat Commun"},{"key":"10.1016\/j.clgc.2023.04.008_bib0008","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1111\/j.1464-410X.2011.10523.x","article-title":"Survival of patients with small cell carcinoma of the prostate during 1973-2003: a population-based study","volume":"109","author":"Deorah","year":"2012","journal-title":"BJU Int"},{"key":"10.1016\/j.clgc.2023.04.008_bib0009","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1053\/hp.2000.7295","article-title":"Neuroendocrine expression in metastatic prostate cancer: evaluation of high throughput tissue microarrays to detect heterogeneous protein expression","volume":"31","author":"Mucci","year":"2000","journal-title":"Hum Pathol"},{"key":"10.1016\/j.clgc.2023.04.008_bib0010","doi-asserted-by":"crossref","first-page":"2492","DOI":"10.1200\/JCO.2017.77.6880","article-title":"Clinical and genomic characterization of treatment-emergent small-cell neuroendocrine prostate cancer: a multi-institutional prospective study","volume":"36","author":"Aggarwal","year":"2018","journal-title":"J Clin Oncol"},{"issue":"suppl 2","key":"10.1016\/j.clgc.2023.04.008_bib0011","doi-asserted-by":"crossref","first-page":"S141","DOI":"10.1093\/annonc\/12.suppl_2.S141","article-title":"Neuroendocrine differentiation in human prostate cancer. Morphogenesis, proliferation and androgen receptor status","volume":"12","author":"Bonkhoff","year":"2001","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clgc.2023.04.008_bib0012","doi-asserted-by":"crossref","first-page":"6916","DOI":"10.1158\/1078-0432.CCR-19-1423","article-title":"The role of lineage plasticity in prostate cancer therapy resistance","volume":"25","author":"Beltran","year":"2019","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clgc.2023.04.008_bib0013","unstructured":"National Comprehensive Cancer Network. Prostate Cancer (Version 4.2022)."},{"key":"10.1016\/j.clgc.2023.04.008_bib0014","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.eururo.2017.06.002","article-title":"Management of patients with advanced prostate cancer: the report of the advanced prostate cancer consensus conference APCCC 2017","volume":"73","author":"Gillessen","year":"2018","journal-title":"Eur Urol"},{"key":"10.1016\/j.clgc.2023.04.008_bib0015","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1038\/nrurol.2014.21","article-title":"Small cell carcinoma of the prostate","volume":"11","author":"Nadal","year":"2014","journal-title":"Nat Rev Urol"},{"key":"10.1016\/j.clgc.2023.04.008_bib0016","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1016\/0959-8049(94)90455-3","article-title":"Activity of docetaxel (Taxotere) in small cell lung cancer. The early clinical trials group of the EORTC","volume":"30A","author":"Smyth","year":"1994","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.clgc.2023.04.008_bib0017","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1056\/NEJMoa041318","article-title":"Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer","volume":"351","author":"Petrylak","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clgc.2023.04.008_bib0018","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1016\/S1470-2045(19)30408-5","article-title":"Cabazitaxel plus carboplatin for the treatment of men with metastatic castration-resistant prostate cancers: a randomised, open-label, phase 1-2 trial","volume":"20","author":"Corn","year":"2019","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clgc.2023.04.008_bib0019","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1093\/annonc\/mdn694","article-title":"Combining carboplatin and etoposide in docetaxel-pretreated patients with castration-resistant prostate cancer: a prospective study evaluating also neuroendocrine features","volume":"20","author":"Loriot","year":"2009","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clgc.2023.04.008_bib0020","doi-asserted-by":"crossref","first-page":"2476","DOI":"10.1093\/annonc\/mdr004","article-title":"Phase II study of carboplatin and etoposide in patients with anaplastic progressive metastatic castration-resistant prostate cancer (mCRPC) with or without neuroendocrine differentiation: results of the French Genito-Urinary Tumor Group (GETUG) P01 trial","volume":"22","author":"Flechon","year":"2011","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clgc.2023.04.008_bib0021","doi-asserted-by":"crossref","first-page":"3621","DOI":"10.1158\/1078-0432.CCR-12-3791","article-title":"Platinum-based chemotherapy for variant castrate-resistant prostate cancer","volume":"19","author":"Aparicio","year":"2013","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clgc.2023.04.008_bib0022","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.1056\/NEJMoa1809064","article-title":"First-line atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer","volume":"379","author":"Horn","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clgc.2023.04.008_bib0023","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1002\/cncr.33328","article-title":"Results of a multicenter, phase 2 study of nivolumab and ipilimumab for patients with advanced rare genitourinary malignancies","volume":"127","author":"McGregor","year":"2021","journal-title":"Cancer"}],"container-title":["Clinical Genitourinary Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1558767323000952?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1558767323000952?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T11:37:09Z","timestamp":1761565029000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1558767323000952"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8]]},"references-count":23,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023,8]]}},"alternative-id":["S1558767323000952"],"URL":"https:\/\/doi.org\/10.1016\/j.clgc.2023.04.008","relation":{},"ISSN":["1558-7673"],"issn-type":[{"value":"1558-7673","type":"print"}],"subject":[],"published":{"date-parts":[[2023,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Outcomes of Second-Line Therapies in Patients With Metastatic de Novo and Treatment-Emergent Neuroendocrine Prostate Cancer: A Multi-Institutional Study","name":"articletitle","label":"Article Title"},{"value":"Clinical Genitourinary Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clgc.2023.04.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}